AstraZeneca starts key study for new cancer drug
24th Nov 2005, 06:40 GMT
LONDON (Reuters) - AstraZeneca has started recruiting patients for a pivotal Phase II/III clinical study of its experimental lung cancer drug AZD2171, Europe's third-biggest drug maker said on Wednesday.
AstraZeneca starts key study for new cancer drug related news:
- FTSE nudges near 4-year highs — Reuters: Business
- Pharmaceuticals spark FTSE rally — BreakingNews.ie - Business
- Major ovarian cancer clinical study announced at Yale using combination drug therapy — EurekAlert! - Medicine and Health
- AstraZeneca Files Suit Against Ranbaxy — RedOrbit News - Health
- Major ovarian cancer clinical study announced at Yale using combination drug therapy, phenoxodiol with docetaxel — Medical News Today RSS/XML Feed
- FTSE ends up after reaching fresh four-year peak — Reuters: Business
- Drug may stem weight loss during radiation treatments — Medical News Today RSS/XML Feed
- Will Herceptin be effective for early breast cancer? — Medical News Today RSS/XML Feed
- Bristol-Myers Squibb drug may prevent weight loss in cancer — Pharmaceutical Business Review Online
- Long-Term Study Proves Tamoxifen Helps Prevent Breast Cancer — iVillage Health & Well-Being News
Latest news from Reuters: Shares:
- FTSE 100 set to edge up
- Playtech to buy Tribeca to join poker top table
- BT applies for long-distance licences in India
- DCC full-year outlook improves
- Wiseman Dairies profits jump
- BHP Billiton venture buys U.S. Gulf acreage
- Dawnay Day Treveria in share placing
- Majestic Wine profit rises
- Shipping broker ACM to float on AIM
- Newspaper round-up